Nasopharyngeal Cancer Recurrent Clinical Trial
Official title:
Single-Arm Study of Toripalimab in Combination With Cisplatin and Gemcitabine in Recurrent Metastatic Nasopharyngeal Carcinoma Systemic Treatment Naïve Participants
This study aims to investigate toripalimab with chemotherapy in participants with nasopharyngeal cancer.
The primary objective of this study is to evaluate the efficacy of toripalimab in combination with chemotherapy (cisplatin and gemcitabine), as measured by objective response rate (ORR) assessed by a Blinded Independent Central Review Committee (BICR) according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 in first-line recurrent metastatic nasopharyngeal cancer participants (both Epstein-Barr virus (EBV) and non-EBV-associated). ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02113423 -
Intensity Modulated Radiotherapy in Recurrent T1-2 Nasopharyngeal Carcinoma
|
N/A |